Skip to content
Loading
French
Spanish
Chinese
Japanese
Korean

IP Services

Trade Secrets

There are many ways in which a company can lose competitive ground through improperly protected trade secrets. Confidential information is often the key to what separates one company’s products and services from another – yet trade secret protection is easily lost if not managed properly.

We assist clients with identifying, managing, and protecting their trade secrets. This includes drafting employee agreements and policies, advising on procedures, and reviewing marketing and trade show materials. We also act as counsel regarding trade secret disputes and litigation.

Have a question for one of our trade secrets professionals? Check out our list below to see which members of our team can help you get started.

Our People

Charles Boulakia

Lawyer, Patent & Trademark Agent - Partner

Toronto

Mitchell Charness

Lawyer, Patent & Trademark Agent - Partner*

Ottawa

Peter Everitt

Lawyer, Patent & Trademark Agent - Partner*

Burlington

Elliott Gold

Lawyer, Patent & Trademark Agent - Partner

Toronto

David Greer

Lawyer, Patent & Trademark Agent - Partner*

Toronto

Abbas Kassam

Lawyer, Trademark Agent - Associate

Toronto

Steven Leach

Lawyer, Patent & Trademark Agent - Partner*

Burlington

Ken Ma

Lawyer, Patent Agent - Associate

Ottawa

Benjamin Mak

Lawyer, Patent & Trademark Agent - Partner

Toronto

Recent IP & Firm News

Criminal Liability for Trade Secrets Offences

Bill C-4, An Act to implement the Agreement between Canada, the United States of America, and the United Mexican States, was passed by the Canadian House of Commons on March 13, 2020.

Read News Item

Update on CUSMA/NAFTA and Bill C-4

On Wednesday, January 29, 2020, Bill C-4 was introduced to implement the Canada - United States – Mexico Agreement Implementation Act (CUSMA).

Read News Item

Without Clear Evidence of its Confidential Nature, Drug Data can be Released Under Access to Information Rules

In Canada, as elsewhere, pharmaceutical companies must submit voluminous information to the Federal government (Health Canada) for approval of a new drug.

Read News Item